Lenvima (lenvatinib) / Eisai, Merck (MSD) 
Welcome,         Profile    Billing    Logout  
 53 Diseases   490 Trials   490 Trials   8927 News 


«12...108109110111112113114115116117118...123124»
  • ||||||||||  Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
    Journal:  Therapeutic options for advanced thyroid cancer. (Pubmed Central) -  Nov 14, 2019   
    The mainstay of treatment for DTC includes a combination of surgery, radioactive iodine (RAI) and levothyroxine suppression...Over the past decade, Identification of genetic mutations in the signaling pathway involved in thyroid tumorigenesis has led to the approval of tyrosine kinase inhibitors (TKIs); Sorafenib and Lenvatinib in RAI-refractory DTC...The approval of TKIs such as Cabozantinib and Vandetanib has introduced an encouraging, novel, systemic therapeutic option for metastatic MTC...The FDA recently approved Dabrafenib plus trametinib for BRAF V600E mutated ATC...Additionally, the review aims to clarify the patient selection criteria for initiation of TKIs and examine the implications, considerations and adverse effects prior to utilizing targeted therapy. Clinical trials are ongoing with promising results and may contribute to the addition of several targeted molecules and immune check point inhibitors to the therapeutic armamentarium for RAI-refractory DTC, medullary and anaplastic thyroid cancer.
  • ||||||||||  Opdivo (nivolumab) / Ono Pharma, BMS
    Biomarker, Review, Journal, PD(L)-1 Biomarker, IO Biomarker:  Systemic Therapy for Advanced Hepatocellular Carcinoma: An Update of a Rapidly Evolving Field. (Pubmed Central) -  Nov 7, 2019   
    Patients intolerant to first-line therapy might benefit from immunotherapy with nivolumab or pembrolizumab...Future studies should focus on identifying reliable biomarkers to predict response to therapy and to better stratify patients at high risk for progression. Multidisciplinary approach is pivotal for successful outcomes in patients with advanced HCC.
  • ||||||||||  Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
    Clinical, Review, Journal:  Targeted agents for second-line treatment of advanced hepatocellular carcinoma. (Pubmed Central) -  Oct 31, 2019   
    Overall, the adverse events reported in these trials were in line with the known safety profiles of the tested agents. After nearly a decade of a certain degree of stagnation, we are now witnessing a period of novel therapeutic advances with multikinase inhibitors and monoclonal antibodies that will likely change the treatment scenario of HCC.
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD), Nexavar (sorafenib) / Bayer, Amgen
    Retrospective data, Journal:  Renal dysfunction in patients with radioactive iodine-refractory thyroid cancer treated with tyrosine kinase inhibitors: A retrospective study. (Pubmed Central) -  Oct 26, 2019   
    According to our program of TKI dose reduction and withdrawal, all patients except 2 with diabetes were successfully continuing treatment.Overall, the present results demonstrated that renal function is negatively affected by long-term TKI treatment for RAI-refractory DTC. However, heightened proteinuria, decreased eGFR and albumin levels, and significant but apparently reversible renal dysfunction were more frequent with lenvatinib than sorafenib.
  • ||||||||||  Clinical, Review, Journal:  Radioactive Iodine-Refractory Differentiated Thyroid Cancer in the Elderly. (Pubmed Central) -  Oct 25, 2019   
    These agents are, however, associated with increased toxicity. The variable nature of disease and toxicity associated with the systemic therapy makes it important to have an individualized approach to management, especially in the elderly population who can be more susceptible to toxicities.
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD), Nexavar (sorafenib) / Bayer, Amgen
    Journal:  Advances in the study of programmed cell death protein 1 and its ligand inhibitors in the treatment of late stage HCC (Pubmed Central) -  Oct 24, 2019   
    Moreover, immune checkpoint is one of the main mechanisms of tumor immune evasion; of which programmed cell death protein 1 and its ligand (PD1/PD-L1) are important immune checkpoint targets, and its related pathway has shown to have an antitumor effect in a variety of solid or hematologic tumors and its inhibitors can effectively exert antitumor immunosuppressive effects. This review summarizes the current role of PD1/PD-L1 inhibitors in the treatment of late stage HCC, and explores the forecasting value of combined therapy strategy for HCC.
  • ||||||||||  Loqtorzi (toripalimab-tpzi) / Shanghai Junshi Biosci, Coherus Biosci
    Trial initiation date, Combination therapy, PD(L)-1 Biomarker:  Toripalimab in Combination With Lenvatinib as Neoadjuvant Therapy in Resectable Hepatocellular Carcinoma (clinicaltrials.gov) -  Oct 21, 2019   
    P1/2,  N=20, Not yet recruiting, 
    This review summarizes the current role of PD1/PD-L1 inhibitors in the treatment of late stage HCC, and explores the forecasting value of combined therapy strategy for HCC. Initiation date: Mar 2019 --> Dec 2019
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Biomarker, Review, Journal, PD(L)-1 Biomarker, IO Biomarker:  Lenvatinib in Management of Solid Tumors. (Pubmed Central) -  Oct 17, 2019   
    In addition, they will learn that different strengths of lenvatinib are prescribed and why. Finally, readers are pointed to the latest efforts to combine lenvatinib and pembrolizumab, as well as to unresolved issues such as long-term side effects/toxicities of this drug.
  • ||||||||||  Opdivo (nivolumab) / Ono Pharma, BMS
    Single centre experience with anti-PD1 therapy in gynaecologic cancers () -  Oct 16, 2019 - Abstract #ESGO2019ESGO_1336;    
    Conclusion In our small cohort of unselected gynaecologic cancer patients treated with anti-PD1 antibodies after failure of standard of care treatments, response rates were highest among cervical cancer patients. Differences in tumour immunogenicity such as PD-L1 expression, human papilloma virus infection, microsatellite instability and POLE mutations may affect response rates.
  • ||||||||||  paclitaxel / Generic Mfg.
    Subungual metastasis of an endometrial carcinoma () -  Oct 16, 2019 - Abstract #ESGO2019ESGO_1231;    
    A weekly Carboplatinum and Paclitaxel chemotherapy with concomitant Denosumab was initiated...As confirmed by the literature, the occurrence of subungual metastasis is precursor to the rapid fatal progression of the disease. Beside the unexpected topography of the metastasis, the absence of an underlying bone involvement and the mild clinical manifestations were singular features of this progression pattern.
  • ||||||||||  Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
    Review, Journal:  Treatment Lines in Hepatocellular Carcinoma. (Pubmed Central) -  Oct 12, 2019   
    In addition, ramucirumab, an angiostatic antibody, also improves survival in second-line systemic therapy...Liver transplantation should always be considered as long-term curative treatment option, especially in T2 patients. In palliative treatment, early response assessment is required to advance patients to the next treatment line before decompensation.
  • ||||||||||  Loqtorzi (toripalimab-tpzi) / Shanghai Junshi Biosci, Coherus Biosci, Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Enrollment change, Metastases:  LTHAIC: HAIC Plus Lenvatinib and Toripalimab for Advanced HCC (clinicaltrials.gov) -  Oct 9, 2019   
    P2,  N=35, Recruiting, 
    Not yet recruiting --> Recruiting N=25 --> 35
  • ||||||||||  Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
    Journal:  Drug resistance profiles of mutations in the RET kinase domain. (Pubmed Central) -  Oct 4, 2019   
    Besides changes in the drug-interacting residues, mutations at distant sites could exert long-range effects resulting in TKI resistance. Among the four TKIs analyzed here, nintedanib remained unaffected by mutations at the three distant sites.
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD), Nexavar (sorafenib) / Bayer, Amgen
    Clinical, Journal:  AFP-producing hepatoid adenocarcinoma (HAC) of peritoneum and omentum: a case report and literature review. (Pubmed Central) -  Oct 3, 2019   
    When the patient shifted to the standard multikinase inhibitors, Sorafenib or Lenvatinib, both treatments were ineffective. HAC is a heterogeneous group of prognostically unfavourable tumours mimicking the histological appearance of HCC, and the treatment outcomes are still unclear.
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Trial completion date, Trial primary completion date, Metastases:  Capecitabine and Lenvatinib With External Radiation in Rectal Adenocarcinoma (clinicaltrials.gov) -  Oct 3, 2019   
    P1,  N=28, Recruiting, 
    HAC is a heterogeneous group of prognostically unfavourable tumours mimicking the histological appearance of HCC, and the treatment outcomes are still unclear. Trial completion date: Nov 2020 --> Nov 2021 | Trial primary completion date: Nov 2019 --> Nov 2020